Protara Q2 2026: $161.9M Cash Runway and Pipeline Milestones on Track
TARA sits 34% above its 52-week low of $2.97.
Summary
Protara Therapeutics posted a Q2 2026 net loss of $21.7M and held $161.9M in cash, expected to fund operations into 2028. Multiple clinical milestones are on track for Q4 2026, including enrollment completions and interim data readouts.
Key Events · Earnings and Guidance · TARA
-
Q2 2026 Financial Results
The net loss widened to $21.7M ($0.36/share) from $15.0M ($0.35/share) in Q2 2025, driven by a rise in R&D expenses to $17.0M from $10.8M as clinical trial activity intensified.
-
Cash Runway into 2028
As of June 30, 2026, cash, cash equivalents, and investments totaled $161.9M, which is expected to support planned operations into 2028.
-
Multiple Q4 2026 Catalysts
All three are expected in Q4 2026: enrollment completion for ADVANCED-2, an update from STARBORN-1, and interim results from THRIVE-3.
-
ADVANCED-3 Trial Redesign
The ADVANCED-3 trial is being redesigned as an exploratory multi-cohort study to expand into high-grade, high-risk BCG-Naïve and BCG-Exposed CIS and papillary patients.
Analysis · TARA · Life Sciences
The second-quarter update reveals a widening net loss—$21.7M versus $15.0M a year ago—as R&D spending climbs to support an advancing late-stage pipeline. With $161.9M in cash, the company has a runway into 2028, providing ample funding for upcoming catalysts. A cluster of milestones is set for Q4 2026: enrollment completion in ADVANCED-2, an update from STARBORN-1, and interim results from THRIVE-3. Meanwhile, the redesign of ADVANCED-3 into an exploratory multi-cohort study could expand the addressable market for TARA-002 in NMIBC. The BLA submission for TARA-002 in LMs is now guided for the second half of 2027. Although insider selling has occurred recently, the primary focus remains on the clinical and regulatory milestones ahead.
At the time of this filing, TARA was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231M. The 52-week trading range was $2.97 to $7.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.